| This is an Open Access article distributed
under the terms of the Creative Commons Attribution License
(https://creativecommons.org/licenses/by-nc/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Patients with transfusion-dependent thalassemia (TDT) risk iron
overload and require iron chelation therapy. Second-line therapy is
warranted for patients demonstrating poor chelation responses.
Patients and Methods
|Table 1. The baseline clinical characteristics of the enrolled OD-DFX nonresponders.|
|Table 2. The clinical efficacies of the twice-daily dosing of deferasirox (TDD-DFX) regimen and other laboratory parameters of the OD-DFX nonresponder group.|
|Figure 1. Changes in the serum ferritin (SF) levels (A) and liver iron concentrations (LICs) (B) of the TDD-DFX responder group.|
|Figure 2. Responses of the patients with transfusion-dependent thalassemia (TDT) to the once-daily deferasirox (OD-DFX) and twice-daily dosing of deferasirox (TDD-DFX) regimens.|